In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AAOS 2015: Hey Big Spender – Spend A Little More Time On EBM

Executive Summary

Insider views on why evidence-based medicine is the future, and why orthopedic physicians need to fully embrace the new focus on quality and value, were central themes at the 2015 American Academy of Orthopaedic Surgeons conference in Las Vegas.

You may also be interested in...



The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.

UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024

Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.

An Ecosystem For Medtech Funding And Innovation Support – BioWales 2024

Creo Medical and Clinithink are among the healthtech innovators who have benefited from funding and advisory support offered by the Development Bank of Wales. All three gave a take on the current funding environment at BioWales in London 2024.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004376

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel